Derek Quick
Uranium/Nuclear & Value Stock Analyst, Trader, Coast Guard Veteran
UnitedHealth and healthcare look set to outperform through year-end, helped by midterm-year seasonality and defensive appeal. Over the last 20 years healthcare has generally done well from July through December in midterm election years. If the S&P 500 rolls into a bear market, UnitedHealth could outperform as investors rotate into defensive sectors. The bull case holds if medical cost ratios fall from AI and GLP-1 use and institutions rotate back into healthcare. x.comÂ
UnitedHealth and Centene should see medical cost ratios fall quickly toward lows as healthcare fraud is finally curbed. Todd Blanche announced charges against 455 defendants over more than $6.5 billion in false claims to Medicare, Medicaid and other programs, and JD Vance said a fugitive behind a $3.7 billion Medicare scheme was brought back to face justice. x.com x.comÂ
Healthcare's rotation from laggard to leader is not done, with the sector coming out of multiyear bases. It has been the most consistent sector in midterm election years for over 30 years, winning 80% of the time in the back half, and 22 healthcare companies beat the S&P 500 in 75%+ of midterms from 1994 to 2022. Focus names range from mature AbbVie, Lilly and UnitedHealth to large caps like Vertex and Amgen and riskier mid caps like Hims & Hers and Oscar Health. Start trimming from November. … Show more
Healthcare looks attractive as volatility has eased in recent weeks while inflows stay steady. Merck is the best-looking pharma play, pharma and biotech are favored, and the broad healthcare sector covers all the bases. x.comÂ
Health care and energy are among the best places to be in a midterm year, with AI keeping tech, industrials and utilities stronger than usual. Since 1994, health care has beaten the S&P 500 by nearly 17% on average in midterm years, averaging 10.7% versus energy's 8.9%. The playbook favors health care, energy, staples and utilities into the vote, then tech, industrials and growth names such as Nvidia, Microsoft, Tesla and Amazon after it, with AI infrastructure the new post-midterm rotation. … Show more
Healthcare's recovery is still in early innings because rotation keeps flowing in. Investors are dumping software for hardware, and those who see hardware as saturated are moving into healthcare as a defensive, long-undervalued sector; the richer hardware gets, the stronger that pull. Oscar Health hit its short-term target early and can reach $40 if this quarter resembles Q1. UnitedHealth, near $410, can aim for $425 to $450 on another beat and raise in Q2. x.comÂ
Managed-care insurance cash flows usually care less about AI bond yields than leveraged hyperscaler debt, making a managed-care sleeve preferable to chasing an AI bounce. UnitedHealth rose about 2.8% alongside Eli Lilly and Walmart after Deutsche Bank upgrades, while semiconductors weakened. x.comÂ
UnitedHealth's earnings visibility, unusually high dividend yield and resumed buybacks make paying under 16x forward earnings not look terrible. Still reasonably confident it is a good place to hide for long-term capital: Hemsley keeps clearing the bar, and UnitedHealth has beaten and raised guidance for three straight quarters. Further derisking remains a risk. x.com x.com x.comÂ
Rotation out of extended semis, AI and tech infrastructure is structural oxygen for a broader bull market, not a bearish signal, as capital flows into software, healthcare, financials and payments. Favored names include Snowflake, Shopify, Datadog and Samsara in enterprise tech; Visa, Robinhood, Affirm, SoFi, Mastercard and American Express in finance; and UnitedHealth, Eli Lilly, Oscar Health, Hims & Hers and Moderna in healthcare. x.comÂ
Healthcare is the clearest place money is moving, and UnitedHealth is the preferred name here. It beat earnings and raised its 2026 profit forecast. x.comÂ
Healthcare and biotech should see a massive capital rotation as aging populations seek to cheat death through cellular immunotherapy, nootropics and personalized medicine, and healthcare holds up in recessions while tech tanks. Eli Lilly is the best big-cap expression of the trade. Money should flow to concierge practices for a K-shaped economy and to new, expensive tailored drugs, while consumer outlets like CVS likely underperform. x.com x.com x.comÂ
Eli Lilly's GLP-1 and metabolic franchise can compound demand and cash flows while rate fears punish leveraged AI stories. It is preferable as a defensive-growth holding into its October 29 earnings over chasing a chip bounce. Continued healthcare volume leadership would support the sleeve; if semiconductors reclaim leadership first, the rotation is already crowded the other way. x.com x.comÂ
